Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of 96,700 restricted stock units (RSUs) to four new employees.

The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employees' acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(4). The RSUs that were granted to the four new employees will vest at a rate of twenty-five percent (25%) on the one-year anniversary of the employees' date of hire, with the remaining shares vesting quarterly over the next three (3) years in equal quarterly amounts, provided the employees continues to serve as an employee of or other service provider to Verastem Oncology on each such vesting date.

About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer.

Contact:

Dan Calkins

Tel: +1 781-469-1694

Email: dcalkins@verastem.com

(C) 2023 Electronic News Publishing, source ENP Newswire